NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of The Bancorp, Inc. ("Bancorp" or "the Company") (NASDAQ:TBBK). Investors who purchased Bancorp securities prior to January 25, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TBBK.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GrafTech International Ltd. ("GrafTech" or "the Company") (NYSE:EAF).

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NASDAQ:FLGT). Investors who purchased Fulgent securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLGT.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Edison International ("Edison" or "the Company") (NYSE:EIX). Investors who purchased Edison securities prior to February 25, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EIX.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. ("PACS Group" or "the Company") (NYSE:PACS). Investors who purchased PACS Group securities prior to April 11, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/PACS.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Dentsply Sirona Inc. ("Dentsply" or "the Company") (NASDAQ:XRAY). Investors who purchased Dentsply securities prior to May 6, 2021, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/XRAY.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ADTRAN Holdings, Inc. ("ADTRAN" or "the Company") (NASDAQ:ADTN). Investors who purchased ADTRAN securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ADTN.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Luminar Technologies, Inc. ("Luminar" or "the Company") (NASDAQ:LAZR). Investors who purchased Luminar securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LAZR.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Schrödinger, Inc. ("Schrödinger" or "the Company") (NASDAQ:SDGR). Investors who purchased Schrödinger securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SDGR.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flowco Holdings Inc. ("Flowco" or "the Company") (NYSE:FLOC). Investors who purchased Flowco securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FLOC.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Healthcare Company, Inc. ("Acadia Healthcare" or "the Company") (NASDAQ:ACHC). Investors who purchased Acadia Healthcare securities prior to February 28, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ACHC.

NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Semler Scientific, Inc. ("Semler" or "the Company") (NASDAQ:SMLR). Investors who purchased Semler securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SMLR.

SAN FRANCISCO, CA / ACCESS Newswire / June 5, 2025 / A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.

NEW YORK, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NANO Nuclear Energy Inc. ("NNE" or "the Company") (NASDAQ:NNE). Investors who purchased NNE securities prior to May 8, 2024, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/NNE.

Is now a good time for traders and advisors to consider amplifying their real estate exposure? There are a few crucial factors that may support doing so.

Despite the tariff volatility, uranium has been a proverbial rock among the crashing waves. The metal has been exhibiting resilience amid renewed interest from investors backed by solid fundamentals.

Forecasts of a recession are looming among market experts. Making sense of recession probabilities can be complex.

I maintain a Buy rating on the stock due to strong revenue growth and expanding profit margins. The company's leadership in its sector and robust product pipeline support long-term earnings potential. Recent quarterly results exceeded expectations, highlighting effective cost controls and resilient demand.

OMAH offers Berkshire Hathaway-focused equity exposure with a 15% targeted annual distribution, achieved via an active options-writing strategy. The fund appeals to income-seeking investors by providing monthly payouts, despite Berkshire itself not paying dividends. The distribution target raises sustainability concerns for those wanting capital preservation, with regard to the possibility of NAV erosion over time.